Plain-English translation of NCT06566755 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called Cadonilimab combined with two other treatments (chemotherapy and bevacizumab) to see if it works better than standard treatment alone for a specific type of advanced colorectal cancer. The trial focuses on cancers that have particular genetic mutations (RAS) or tumors located on the right side of the colon. Researchers want to learn if adding this new medication helps patients live longer and controls their cancer better.
Most people with advanced colorectal cancer that has these specific characteristics don't respond well to standard treatments alone, and their cancer often comes back or spreads. This trial exists to see if combining a newer immunotherapy drug with existing treatments can improve outcomes for patients who have limited options.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions every 3 weeks for 4 to 8 cycles (about 3 to 6 months), including the new medication, chemotherapy, and bevacizumab. After that initial treatment period, you would continue with a maintenance phase receiving the medication, one chemotherapy drug by mouth, and bevacizumab every 3 weeks for as long as your cancer responds well. Throughout the trial, you would have regular blood tests, imaging scans, and doctor visits to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China